Abstract Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance. The RuxoBEAT trial (NCT02577926, registered on October 1, 2015, at clinicaltrials.gov) is a […]
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials and new drugs in development for 2021 and beyond. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a […]
What are Clinical Trials? by Lou Ann Donovan Clinical trials also called interventional clinical studies involve research using participants. Through clinical trials, doctors find new ways to improve treatments and quality of life for people diagnosed with a type of blood cancer Myeloproliferative Neoplasms (MPNs). The participants receive specific interventions, such as drugs according to […]
Authors: Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, Mads Hald Andersen Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer Abstract There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this […]
Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their Investigational New Drug (IND) application providing clearance to proceed with the clinical development of IMG-7289 in the U.S. The IND supports the company’s ongoing Phase 1/2 clinical trial of […]
New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run by pharma mogul Mori Arkin, and US-based venture firm Primera Capital. The money will be used to […]
Site by: Kaleidoscopic
